Recently published results have shown that axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is active and safe in patients with refractory large B-cell lymphoma.

中文翻译：

---

CAR T细胞治疗难治性大B细胞淋巴瘤

最近发表的结果表明，抗癌的大B细胞淋巴瘤患者中，自体抗CD19嵌合抗原受体（CAR）T细胞疗法axicabtagene ciloleucel（axi-cel）是有效且安全的。